drugset

drugset / Trial / NCT05580666

Reducing Mortality in Adults With Advanced HIV Disease (REVIVE)

NCT05580666 ↗

Phase 3 Recruiting 8000 enrolled Population Health Research Institute

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A double blinded, placebo-controlled, multicenter trial to evaluate effectiveness of azithromycin prophylaxis on mortality in advanced HIV.

Timeline

Start: 2023-05-08
Primary completion: 2028-11-30
Completion: 2029-05-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Azithromycin	Small molecule	250 mg	Oral

Indications